Purdue Pharma, L.P., Purdue Pharma, Inc., and Purdue Frederick Company

This pharmaceutical company allegedly encouraged physicians to prescribe OxyContin for use every eight hours instead of the 12 hour dose approved by the FDA. Although OxyContin is a Schedule II narcotic with an abuse profile and addictive qualities, Purdue promoted it as a first-choice analgesic for treatment of a wide variety of pain symptoms, minimizing the known risks. This was a multistate case. Purdue Pharma paid $19.5 million to 26 states, including Tennessee and the District of Columbia. Tennessee received $719,500 from the settlement.

Press Release

• Tennessee, 25 Other States, D.C. Reach Agreement with Drug Company For Advertising Practices Regarding Concerns with Purdue Pharma’s Pain Drug, OxyContin (#07-18, May 8, 2007)

State Court Filings in Purdue Pharma - OxyContin

• Complaint (May 8, 2007)
• Agreed Final Judgment (May 8, 2007)
  

This list includes only significant filings and is not intended to be a complete record of the matter.